Denosumab and fracture risk in women with breast cancer
Mené en Autriche et en Suède sur 3 420 patientes atteintes d'un cancer du sein HR+ après la ménopause et traitées à l'aide d'inhibiteurs de l'aromatase, cet essai de phase III évalue l'efficacité, du point de vue du délai avant l'observation d'une première fracture, et la toxicité du dénosumab en traitement adjuvant
Aromatase inhibitors reduce endogenous serum oestrogen concentrations and are associated with accelerated bone loss, leading to a decrease in bone mineral density and increased fracture risk. As a result, bone-targeted treatments have been tested in randomised clinical trials, at doses and schedules roughly equivalent to those used for the treatment of postmenopausal osteoporosis, to assess their value in reversing this unwanted treatment complication. Data from randomised trials indicate that both bisphosphonates and denosumab can prevent abnormal bone loss.
The Lancet , commentaire, 2014